Abstract
Background
The tall cell variant of papillary thyroid carcinoma (PTC) is as an aggressive histological variant. The proportion of tall cells needed to influence prognosis is debated.
Methods
Patients with PTC and tall cells, defined as having a height-to-width ratio of ≥ 3:1, seen at a high-volume center between 2001 and 2015, were reviewed. Specimens were classified as (1) focal tall cell change, containing < 30% of tall cells; (2) tall cell variant, ≥ 30% of tall cells; and (3) control cases selected from infiltrative classical PTCs without adverse cytologic features. Univariate, sensitivity, and multivariate analyses were performed with persistent/recurrent disease as the primary outcome.
Results
We identified 96 PTCs with focal tall cell change, 35 with the tall cell variant and 104 control cases. Factors associated with poor clinical prognosis were significantly greater in those with focal tall cell change and tall cell variants. Regarding primary outcome, hazard ratios were 2.3 (95% confidence interval [CI] 1.0–5.7) for focal tall cell change, and 3.4 (95% CI 1.2–8.7) for tall cell variants compared with controls. Five-year disease-free survival was higher for the control group (92.7%, CI 87.4–98.0) compared with focal tall cell change (76.3%, CI 66.1–86.5) and the tall cell variant (62.2%, CI 43.2–81.2). When stratified in groups consisting of tall cell proportions (< 10%, 10–19%, 20–29% and ≥ 30%), identification of ≥ 10% tall cell change was associated with worse outcome (p = 0.002).
Conclusions
PTCs with ≥ 10% tall cell change have worse prognosis than those without tall cells. Our data indicate that thyroid cancer management guidelines should consider PTCs with focal tall cell change outside of the low-risk classification.
Similar content being viewed by others
References
Clark O, Duh Q-Y, Kebebew E, Gosnell J, Shen W. Textbook of endocrine surgery, 3rd edn. Kathmandu: Jaypee Brothers Medical Publishers; 2016.
Lam AK, Lo C-YY, Lam KS. Papillary carcinoma of thyroid: A 30-yr clinicopathological review of the histological variants. Endocr Pathol. 2005;16(4):323–30.
Hawk WA, Hazard JB. The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q. 1976;43(4):207–16.
Ghossein R, Livolsi VA. Papillary thyroid carcinoma tall cell variant. Thyroid. 2008;18(11):1179–81.
Solomon A, Gupta PK, LiVolsi VA. Distinguishing tall cell variant of papillary thyroid carcinoma from usual variant of papillary thyroid carcinoma in cytologic specimens. Diagn Cytopathol. 2002;27(3):143–8.
Erler P, Keutgen XM, Crowley MJ, et al. Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer. Surgery. 2014;156(6):1342.
Min HS, Lee C, Jung KC. Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. J Korean Med Sci. 2013;28:534–41.
Oh W, Lee Y, Cho U, et al. Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features. Korean J Pathol. 2014;48(3):201.
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–90.
van den Brekel MW, Hekkenberg RJ, Asa SL, Tomlinson G, Rosen IB, Freeman JL. Prognostic features in tall cell papillary carcinoma and insular thyroid carcinoma. The Laryngoscope. 1997;107(2):254–9.
Hunt JL. Unusual thyroid tumors: a review of pathologic and molecular diagnosis. Expert Rev Mol Diagn. 2005;5(5):725–34.
Ghossein RA, Leboeuf R, Patel KN, et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid. 2007;17(7):655–61.
Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head Neck. 2011;33(7):1052–59.
Carling T, Ocal IT, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg. 2007;31(5):916–23.
Wang X, Cheng W, Liu C, Li J. Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology. Oncotarget. 2016;7(26):40792–9.
Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88(11):5399–404.
Akslen LA, LiVolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer. 2000;88(8):1902–8.
Guan H, VandenBussche CJ, Erozan YS, et al. Can the tall cell variant of papillary thyroid carcinoma be distinguished from the conventional type in fine needle aspirates? A cytomorphologic study with assessment of diagnostic accuracy. Acta Cytol. 2013;57(5):534–42.
Michels JJ, Jacques M, Henry-Amar M, Bardet S. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol. 2007;38:212–9.
Terry JH SJS, Karkowski FJ, Suarez JR, Yassa NH, Platica CD, Marti JR. all cell papillary thyroid cancer: incidence and prognosis. Am J Surg. 1994;168(5):459–61.
Axelsson TA, Hrafnkelsson J, Olafsdottir EJ, Jonasson JG. Tall cell variant of papillary thyroid carcinoma: a population-based study in Iceland. Thyroid. 2014;25(2):216–220.
Hernandez-Prera JC, Machado RA, Asa SL, et al. Pathologic reporting of tall-cell variant of papillary thyroid cancer: Have we reached a consensus? Thyroid. 2017;27(12):1498–504.
Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs, 4th edn. Lyon: IARC; 2017.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
Beninato T, Scognamiglio T, Kleiman DA, et al. Ten percent tall cells confer the aggressive features of the tall cell variant of papillary thyroid carcinoma. Surgery. 2013;154(6):1331.
Ganly I, Ibrahimpasic T, Rivera M, et al. Prognostic implications of papillary thyroid carcinoma with tall-cell features. Thyroid. 2014;24(4):662–70.
Dettmer MS, Schmitt A, Steinert H, et al. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocr Relat Cancer. 2015;22(3):419–29.
Morris LGT, Shaha AR, Tuttle MR, Sikora AG, Ganly I. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid. 2010;20(2):153–8.
Chung YJ, Lee JS, Park SY, et al. Histomorphological factors in the risk prediction of lymph node metastasis in papillary thyroid carcinoma. Histopathology. 2013;62(4):578–88.
Leung AK, Chow S-MM, Law SC. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. The Laryngoscope. 2008;118(1):32–8.
Prendiville S, Burman KD, Ringel MD, et al. Tall cell variant: an aggressive form of papillary thyroid carcinoma. Otolaryngol Head Neck Surg. 2000;122(3):352–7.
Acknowledgment
This project was supported by the Foundation ‘De Drie Lichten’ in The Netherlands (PJB).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Disclosures
Pim J. Bongers, Wouter P. Kluijfhout, Raoul Verzijl, Mattan Lustgarten, Marloes Vermeer, David P. Goldstein, Karen Devon, Lorne E. Rotstein, Sylvia L. Asa, James D. Brierley, Richard W. Tsang, Shereen Ezzat, Menno R. Vriens, Ozgur Mete, and Jesse D. Pasternak have no disclosures to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bongers, P.J., Kluijfhout, W.P., Verzijl, R. et al. Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease. Ann Surg Oncol 26, 2533–2539 (2019). https://doi.org/10.1245/s10434-019-07444-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-019-07444-2